Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Reduced intensity radio-chemotherapy for stage IIA/B seminoma
2019-000514-11Phase 2Active
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2019
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of cisplatin, etoposide and carboplatin in Seminomatous germ cell testicular cancer and testicular cancer (2 cohorts), sponsored by Swiss Group for Clinical Cancer Research. Primary endpoint: Primary efficacy endpoint. Started Oct 2019; status: active.
02
Drugs
cisplatinetoposidecarboplatin
03
Conditions
Seminomatous germ cell testicular cancertesticular cancer
Beyond the preview
Go deeper on 2019-000514-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000514-11.